Imatinib induced Stevens-Johnson syndrome: Lack of recurrence following re-challenge with a lower dose [2]

Indian Journal of Dermatology, Venereology and Leprology

Volumn 71, Issue 4, 2005, Pages 288-289

  Pavithran, Keechilat ^a   Thomas, Mathew ^b  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^b GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

ADULT; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DRUG INDUCED DISEASE; EDEMA; EPIDERMOLYSIS; ERYTHEMA NODOSUM; EXFOLIATIVE DERMATITIS; HUMAN; HYPERPIGMENTATION; LETTER; LICHENOID ERUPTION; MALE; PRURITUS; PSEUDOLYMPHOMA; PUSTULOSIS; RASH; RECURRENT DISEASE; SKIN DEFECT; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; VASCULITIS;

EID: 23944519724     PISSN: 03786323     EISSN: None     Source Type: Journal    
DOI: 10.4103/0378-6323.16628     Document Type: Letter

References (14)

1. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6.
2. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia. Dermatology 2001;203:57-9.
3. Ena P, Chiarolini F, Siddi GM, Cossu A. Oral lichenoid eruption secondary to imatinib (Glivec). Dermatolog Treat 2004;15:253-5.
4. Hamm M, Touraud JP, Mannone L, Klisnick J, Ponnelle T, Lambert D. Imatinib-induced purpuric vasculitis. Ann Dermatol Venereol 2003;130:765-7.
5. Clark SH, Duvic M, Prieto VG. Mycosis fungoides-like reaction in a patient treated with Gleevec. J Cutan Pathol 2003;30:279-81.
6. Schaich M, Schakel K, Illmer T, Ehninger G, Bornhauser M. Severe epidermal necrolysis after treatment with imatinib and consecutive allogeneic hematopoietic stem cell transplantation. Ann Hematol 2003;82:303-4.
7. Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7.
8. Drummond A, Micallef-Eynaud P, Douglas WS, Hay I, Holyoake TL, Drummond MW. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec). Br J Haematol 2003;120:911-3.
9. Banka N, Aljurf M, Hamadah I. Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign. Dermatology 2003;207:329-30.
10. Sanchez-Gonzalez B, Pascual-Ramirez JC, Fernandez-Abellan P, Belinchon-Romero I, Rivas C, Vegara-Aguilera G. Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia. Blood 2003;101:2446.
11. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002;117:620-2.
12. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002;100:3434-5.
13. Vidal D, Puig L, Sureda A, Alomar A. STI571-Induced Stevens-Johnson syndrome. Br J Haematol 2002;119:274-5.
14. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001;345:618-9.